Close

Form 6-K GLAXOSMITHKLINE PLC For: Nov 14

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/17/2024

1. UAL
2. JBHT
3. TSLA
4. SAGE
5. TRV
6. SLG
7. PLD
8. IBKR
9. ASML
10. BAC


November 14, 2014 8:18 AM EST

FORM 6-K
�
�
SECURITIES AND EXCHANGE COMMISSION(
Washington D.C. 20549
�
�
Report of Foreign Issuer
�
�
Pursuant to Rule 13a-16 or 15d-16 of(
the Securities Exchange Act of 1934
�
�
�
For period ending�November 2014
�
GlaxoSmithKline plc
(Name of registrant)(

�
�
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)(

�
�
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F(

�
�
Form 20-F x��� �Form 40-F(
�
--(
�
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.(

�
�
Yes����� No x
--
�
�
�


�

As a result of an administrative error by the Company's external share plan administrator, in connection with the number of shares actually sold, this announcement replaces the original announcement released on 23 October 2014
�
GlaxoSmithKline plc
�
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
�
In accordance with DTR 3.1.4R(1)(a) I give below details of changes in the interests of Sir Andrew Witty, a Director, in the Ordinary Shares of GlaxoSmithKline plc (the "Company"):
�
The exercise of options over 77,500 Ordinary Shares on 23 October 2014, granted on 2 December 2004 under the GlaxoSmithKline Share Option Plan at a price of �11.23 per share, and the sale of 69,905 Ordinary Shares at a price of �13.84 per share on 23 October 2014.
�
The Company was advised of the revised transaction details on 13 November 2014.
�
V A Whyte
Company Secretary
�
14 November 2014

�


�
�
SIGNATURES
�
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.(


�
�
GlaxoSmithKline plc
(Registrant)(

Date:�November 14,�2014�
�
�
By:�VICTORIA WHYTE
----------------------
�
�
Victoria�Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings